GXHPC1®

GXHPC1® is a novel, first-in-class autologous adipose-derived stem cell therapy developed for the treatment of liver cirrhosis. Pre-clinical research has demonstrated that GXHPC1® can ameliorate hepatic inflammation and reverse liver fibrosis.

 
In a phase I clinical trial, GXHPC1® through intrahepatic injection (IH) was shown to be safe, with no significant safety issues reported. The results demonstrated that GXHPC1® showed a tendency for improvement of liver function, METAVIR score, Child–Pugh score, MELD score, and quality of life for patients with liver cirrhosis, suggesting its potential as a treatment for liver cirrhosis (Ko-Chang Huang, 2019). Currently, GXHPC1® is undergoing phase II clinical trials (NCT04088058), and the dose is escalated to 200 million cells.

 
Liver cirrhosis has very limited option for treatment at present, with liver transplantation being the only option. However, liver transplantation comes with a low success rate and requires lifelong use of anti-rejection drugs. In contrast, stem cell therapy represents a novel treatment method. GXHPC1® has been confirmed through animal experiments to improve liver fibrosis, promote liver cell regeneration approximately 63%, and enhance liver function indices. These research results have been published in academic journals and have led to the acquisition of invention patents.